Browsing Tag

Nasdaq:PHVS

Pharvaris Presents Clinical Data at the 2023 U.S. HAEA National Summit

Eli Pacheco Jul 21, 2023 0

ZUG, Switzerland, July 21, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent…

Health

Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand…

Eli Pacheco Jun 26, 2023 0

ZUG, Switzerland, June 26, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent…

Health

Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for…

Eli Pacheco Dec 8, 2022 0

Primary endpoint met, substantially reducing HAE attack symptomsAll secondary endpoints metPHVS416 was well tolerated at all dose levelsPharvaris to host a conference call today at 8:00…

Health

Pharvaris Presents Clinical Data on Oral PHA121 Supporting the Prophylactic Treatment…

Eli Pacheco Jul 10, 2021 0

ZUG, Switzerland, July 10, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral…